Full results from the positive Phase III KALOS and LOGOS trials have been published in The Lancet Respiratory Medicine.

Budesonide–formoterol reliever therapy significantly reduces airway inflammation vs SABA in adults with mild to moderate asthma using ICS.

Full results from the positive Phase III KALOS and LOGOS trials published in The Lancet Respiratory Medicine showed AstraZeneca’s BREZTRI Aerosphere (budesonide/glycopyrronium/formoterol fumarate or ...

(Alliance News) - Astrazeneca on Friday hailed positive results from a phase-three trial of its asthma treatment breztri aerosphere. Shares in the Cambridge, England-based pharmaceutical company rose ...

AstraZeneca announced on Thursday that it plans to invest more than 100 billion yuan ($15 billion) in China by 2030 to expand its pharmaceutical manufacturing and research and development footprint.

AstraZeneca Plc AZN on Tuesday reported fourth-quarter 2025 sales of $15.50 billion, up 4% year over year (+2% at constant currency or cc), almost in line with the consensus of $15.49 billion. The ...

AstraZeneca AZN reported fourth-quarter 2025 core earnings of $2.12 per share, which missed the Zacks Consensus Estimate of $2.18 per share. Earnings rose 1% year over year on a reported basis but ...

Besides Wall Street's top-and-bottom-line estimates for Astrazeneca (AZN), review projections for some of its key metrics to ...

AZN gears up for Q4 results as cancer, diabetes and rare disease drugs drive sales expectations ahead of the Feb. 10 earnings report.

Adults with mild-to-moderate asthma who take regular inhaled corticosteroids can achieve greater control of airway inflammation by also using the 2-in-1 combination budesonide-formoterol as a reliever ...

Analysis finds modest benefit that researchers say warrants formulary changes ...

AstraZeneca said it entered into a collaboration and licensing agreement with China's CSPC Pharmaceuticals to gain rights outside of China to a portfolio of experimental obesity and diabetes drugs, in ...